USH2A — Usher syndrome type 2A

The USH2A gene provides instructions for making a protein called usherin, which is an important component of basement membranes in the inner ear and the retina (the light-sensitive tissue at the back of the eye). Usherin plays a crucial role in the development and maintenance of cells in these sensory organs. In the inner ear, it helps form the hair bundles needed for hearing, while in the retina, it is essential for the survival and function of photoreceptors, the cells that detect light. When the USH2A gene is mutated, the usherin protein may be abnormally short, nonfunctional, or missing entirely. This disrupts the normal structure and function of the inner ear and retina. Depending on the specific mutation, this can lead to either Usher syndrome type IIA, which involves both hearing loss from birth and progressive vision loss, or nonsyndromic retinitis pigmentosa, which causes vision loss without affecting hearing. The vision loss typically begins with night blindness and loss of peripheral vision, eventually affecting central vision. Conditions caused by USH2A mutations are inherited in an autosomal recessive pattern. This means that a person must inherit two mutated copies of the gene (one from each parent) to develop the condition. Parents who carry only one mutated copy are called carriers; they typically do not show any symptoms but have a 25% chance with each pregnancy of passing the condition to their child. Genetic testing can help families understand their specific mutations and inheritance risks.

Gene description: Encodes usherin, a large extracellular matrix protein vital for the structure and function of the photoreceptor cilium.

Patient and family guide: The USH2A gene provides instructions for making a protein called usherin, which is an important component of basement membranes in the inner ear and the retina (the light-sensitive tissue at the back of the eye). Usherin plays a crucial role in the development and maintenance of cells in these sensory organs. In the inner ear, it helps form the hair bundles needed for hearing, while in the retina, it is essential for the survival and function of photoreceptors, the cells that detect light. When the USH2A gene is mutated, the usherin protein may be abnormally short, nonfunctional, or missing entirely. This disrupts the normal structure and function of the inner ear and retina. Depending on the specific mutation, this can lead to either Usher syndrome type IIA, which involves both hearing loss from birth and progressive vision loss, or nonsyndromic retinitis pigmentosa, which causes vision loss without affecting hearing. The vision loss typically begins with night blindness and loss of peripheral vision, eventually affecting central vision. Conditions caused by USH2A mutations are inherited in an autosomal recessive pattern. This means that a person must inherit two mutated copies of the gene (one from each parent) to develop the condition. Parents who carry only one mutated copy are called carriers; they typically do not show any symptoms but have a 25% chance with each pregnancy of passing the condition to their child. Genetic testing can help families understand their specific mutations and inheritance risks.

Gene function: USH2A is critical for maintaining the structural integrity of the photoreceptor outer segment and the connection between the inner and outer segments. It interacts with other Usher proteins to form a protein complex essential for photoreceptor development and survival, preventing retinal degeneration.

Protein structure: The USH2A gene encodes usherin, an extraordinarily large single-pass transmembrane protein. The full-length human usherin protein (isoform b) consists of 5,202 amino acids with a predicted molecular mass of over 500 kDa. Its structure includes a signal peptide, an N-terminal globular domain, 10 laminin epidermal growth factor (EGF)-like domains, 35 fibronectin type III (FN3) motifs, 2 laminin G domains, a transmembrane region, and a short intracellular C-terminal domain containing a PDZ-binding motif. A shorter, secreted isoform (isoform a) of 1,546 amino acids also exists, lacking the transmembrane and intracellular domains. Usherin functions as a key structural component and scaffold protein. Through its extracellular domains, it interacts with other extracellular matrix proteins like collagen IV and fibronectin. Its intracellular PDZ-binding motif allows it to bind to scaffold proteins such as whirlin (WHRN) and harmonin (USH1C). In the retina, usherin forms the Usher protein network (interactome) at the periciliary membrane complex by interacting with ADGRV1 and whirlin, while in the inner ear, it forms the ankle links connecting adjacent stereocilia in developing hair cells.

Molecular function: At the molecular and cellular level, usherin is a critical structural and scaffolding protein that maintains the integrity and function of sensory cells. In the retina, usherin localizes to the periciliary membrane complex at the connecting cilium of photoreceptors. Here, it forms a tripartite complex with ADGRV1 (VLGR1) and whirlin. This Usher protein network is thought to anchor the periciliary membrane to the axoneme and play a role in the intracellular transport of proteins from the inner segment to the outer segment of photoreceptors. It may also be involved in regulating autophagy and maintaining the structural stability of the photoreceptor cells under light stress. In the inner ear, usherin is essential for the proper development of cochlear hair cells. It localizes to the base of differentiating stereocilia, where it forms the ankle links—fibrous connections that hold adjacent stereocilia together. These ankle links are crucial for the correct organization, growth, and orientation of the mechanosensitive hair bundles during early postnatal development. The interaction of usherin's intracellular domain with PDZ-domain proteins like whirlin and harmonin anchors these extracellular links to the actin cytoskeleton within the stereocilia. Loss of functional usherin disrupts these multiprotein complexes. In the retina, this leads to defective protein transport, structural disorganization of the connecting cilium, and eventual apoptosis of rod and cone photoreceptors. In the inner ear, the absence of usherin prevents the formation of ankle links, resulting in disorganized hair bundles that cannot properly transduce sound waves into electrical signals, leading to congenital sensorineural hearing loss.

Expression pattern: The USH2A gene is predominantly expressed in the retina and the inner ear, corresponding to the primary tissues affected in Usher syndrome. In the retina, USH2A mRNA and usherin protein are highly expressed in the photoreceptor cells (both rods and cones), specifically localizing to the periciliary membrane complex at the connecting cilium. Expression is also found in the basement membrane (Bruch's membrane) underlying the retinal pigment epithelium (RPE). In the inner ear, USH2A is expressed in the cochlear and vestibular hair cells during development. The protein transiently localizes to the ankle links of the stereocilia hair bundles during early postnatal development in mice, which is a critical period for hair bundle maturation. Beyond the sensory organs, USH2A expression has also been detected at lower levels in various other tissues, including the testis, liver, kidney, and intestinal tissues, where it is a component of basement membranes, though mutations do not typically cause clinical symptoms in these organs.

Mutation spectrum: The USH2A gene exhibits a highly diverse mutation spectrum, with over 1,000 distinct pathogenic variants identified to date. These include missense, nonsense, frameshift (insertions/deletions), splice-site mutations, and deep intronic variants that cause pseudoexon inclusion. Large genomic rearrangements and copy number variations (CNVs), such as multi-exon deletions or duplications, account for approximately 6-9% of pathogenic alleles. Mutations are distributed throughout the gene's 73 exons, though certain regions, such as exon 13, are known hotspots. Several founder mutations have been identified in specific populations. The most common mutation worldwide is c.2299delG (p.Glu767Serfs*21) in exon 13, which accounts for 15-30% of all disease alleles in populations of European descent. Another frequent variant is the missense mutation c.2276G>T (p.Cys759Phe), also in exon 13. In East Asian populations, the splice-site mutation c.8559-2A>G is a major founder mutation, accounting for nearly 20% of USH2A alleles in Chinese and Japanese patients. Deep intronic variants, such as c.7595-2144A>G, have also been recognized as significant contributors to the mutation burden.

Pathogenic variants: 1. p.Glu767Serfs*21 (c.2299delG): The most common USH2A mutation globally, particularly in European populations. It causes a frameshift and premature truncation in exon 13. When homozygous or compound heterozygous with another severe mutation, it typically causes classic Usher syndrome type IIA. 2. p.Cys759Phe (c.2276G>T): A common missense mutation in exon 13. It is frequently associated with nonsyndromic autosomal recessive retinitis pigmentosa (arRP) when present in a homozygous state or in trans with another mutation, as it likely retains some residual protein function that preserves hearing. 3. c.8559-2A>G: A highly prevalent splice-site founder mutation in East Asian (Chinese and Japanese) populations. It disrupts normal RNA splicing and is a major cause of both USH2 and arRP in these demographics. 4. p.Cys319Tyr (c.956G>A): A well-characterized missense mutation that affects protein folding and stability. It is often found in patients with USH2A-related retinal degeneration. 5. c.7595-2144A>G: A deep intronic mutation that creates a cryptic splice site, leading to the inclusion of a pseudoexon and premature protein truncation. It is one of the most common intronic variants causing USH2A disease.

Clinical significance: Mutations in the USH2A gene are the leading cause of Usher syndrome type II (USH2A) and one of the most common causes of nonsyndromic autosomal recessive retinitis pigmentosa (arRP). Usher syndrome type II is characterized by congenital, bilateral, mild-to-moderate sensorineural hearing loss in the low frequencies and severe-to-profound hearing loss in the high frequencies. Unlike Usher syndrome type I, vestibular function is typically normal. The retinal degeneration in USH2A manifests as retinitis pigmentosa, usually beginning with night blindness (nyctalopia) in adolescence or early adulthood, followed by progressive constriction of the peripheral visual field, and eventually affecting central vision and visual acuity in later decades. In patients with nonsyndromic USH2A-arRP, hearing is preserved, and the clinical presentation is limited to the eye. The onset of visual symptoms in isolated arRP can sometimes be later than in syndromic USH2A, but the progression of retinal degeneration is similar. The severity and rate of progression of vision loss can vary significantly among individuals, even within the same family. Systemic features outside of the auditory and visual systems are generally absent, despite the gene's expression in other tissues.

Inheritance: Autosomal recessive

Chromosomal location: 1q41

Genotype-phenotype correlations: There is a well-established genotype-phenotype correlation for USH2A mutations, primarily based on the residual function of the usherin protein. The clinical phenotype (Usher syndrome vs. nonsyndromic RP) is largely determined by the combination of alleles. Patients with two severe, truncating mutations (nonsense, frameshift, or canonical splice-site) typically develop Usher syndrome type II, as the complete loss of functional usherin affects both the inner ear and the retina. Conversely, the presence of at least one "mild" missense mutation (such as p.Cys759Phe) in trans with a severe mutation, or homozygosity for mild missense mutations, is generally associated with nonsyndromic retinitis pigmentosa. It is hypothesized that these missense variants produce a partially functional protein that is sufficient for the normal development of cochlear hair cells (preserving hearing) but insufficient for the long-term maintenance of photoreceptors, leading to progressive retinal degeneration. Additionally, some specific mutations may cause a later onset or slower progression of visual field loss.

Research and therapeutic approaches: Currently, there are no approved treatments to cure or halt the progression of USH2A-related vision loss, though hearing aids and cochlear implants effectively manage the hearing impairment. However, several therapeutic strategies are in preclinical and clinical development. Because the USH2A coding sequence (15.6 kb) exceeds the packaging capacity of standard adeno-associated virus (AAV) vectors (limit ~4.7 kb), traditional single-vector gene replacement therapy is not feasible. Alternative gene therapy approaches being explored include dual-AAV systems, lentiviral vectors, and non-viral episomal vectors (e.g., S/MAR DNA plasmids) to deliver the full-length gene. Antisense oligonucleotides (ASOs) represent a promising targeted approach. Ultevursen (QR-421a) is an investigational RNA therapy designed to induce the skipping of exon 13, which contains many common mutations (including c.2299delG and p.Cys759Phe). By skipping this exon, a slightly shorter but functional usherin protein is produced. This therapy has entered clinical trials (e.g., Phase 1/2 trial NCT03780257). Other strategies under investigation include CRISPR/Cas9 gene editing to correct specific mutations in patient-derived cells, and nonsense suppression therapy (translational read-through inducing drugs like ataluren) for patients with premature stop codons.

Diagnostic testing: Diagnosis of USH2A-related disorders involves a combination of clinical evaluation (audiometry, electroretinography, optical coherence tomography, and visual field testing) and molecular genetic testing. Genetic testing is essential to confirm the diagnosis, determine the specific subtype of Usher syndrome or RP, and guide prognosis and potential eligibility for clinical trials. Testing approaches typically include targeted next-generation sequencing (NGS) panels for inherited retinal diseases and deafness, or whole-exome sequencing (WES). Because USH2A is a large gene with deep intronic mutations and copy number variations (CNVs), specialized testing such as whole-genome sequencing (WGS) or targeted deletion/duplication analysis may be required if only one or no mutations are found on standard panels. Genetic counseling is highly recommended for affected individuals and their families to discuss the autosomal recessive inheritance pattern, carrier testing for at-risk relatives, and family planning options.

Animal models: Animal models have been crucial for understanding USH2A disease mechanisms, though they present some challenges. Mouse models, such as the Ush2a knockout mouse, exhibit mild and slowly progressive retinal degeneration and high-frequency hearing loss. While they have been useful for studying the localization of usherin and its interaction with other Usher proteins, the retinal phenotype in mice is much less severe than in humans, limiting their utility for testing vision-rescuing therapies. Zebrafish models (ush2a mutants) have proven to be highly valuable. Zebrafish ush2a mutants display early-onset retinal dysfunction, reduced electroretinogram (ERG) responses, and progressive photoreceptor degeneration that is exacerbated by light exposure. They also show defects in hair cell function. Because their retinal phenotype is more pronounced and rapid than in mice, zebrafish are extensively used to evaluate the efficacy of novel therapies, including large gene augmentation, ASOs, and gene editing strategies.

Population genetics: USH2A mutations are highly prevalent in the general population. Recent large-scale genomic analyses estimate that the worldwide carrier frequency for pathogenic USH2A variants is approximately 1 in 150 individuals. The genetic prevalence of USH2A-related disease is estimated to be around 1 in 29,000 globally. Carrier frequencies and specific mutation distributions vary significantly by ethnicity. For example, the c.2299delG mutation is a major founder allele in populations of European descent, while the c.8559-2A>G mutation is highly prevalent in East Asian populations, with carrier rates for USH2A mutations in Chinese cohorts estimated at around 1 in 170. This high carrier frequency underscores the importance of USH2A as a major contributor to the global burden of inherited retinal diseases.

Selected references: 1. Eudy JD, et al. Mutation of a gene encoding a protein with extracellular matrix motifs in Usher syndrome type IIa. Science, 1998. PMID: 9616113 2. van Wijk E, et al. Identification of 51 novel exons of the Usher syndrome type 2A (USH2A) gene that encode multiple conserved functional domains and that are mutated in patients with Usher syndrome type II. Am J Hum Genet, 2004. PMID: 15015129 3. Lenassi E, et al. A detailed clinical and molecular survey of subjects with nonsyndromic USH2A retinopathy reveals an allelic hierarchy of disease-causing variants. Eur J Hum Genet, 2015. PMID: 25689926 4. Toualbi L, et al. USH2A-retinopathy: From genetics to therapeutics. Exp Eye Res, 2020. PMID: 32979350 5. Hanany M, et al. Worldwide carrier frequency and genetic prevalence of autosomal recessive inherited retinal diseases. Proc Natl Acad Sci U S A, 2020. PMID: 31964843 6. Toms M, et al. Successful large gene augmentation of USH2A with non-viral episomal vectors. Mol Ther, 2023. PMID: 37337354 7. Li W, et al. Genetic Characteristics and Variation Spectrum of USH2A-Related Inherited Retinal Diseases in a Large Chinese Cohort. Front Genet, 2022. PMID: 36105121